The perspective on seeking investment varies company by company. Still, a common theme exists that it is necessary to ensure knowledge of the market and the actual value of one's technology and that the company's cash runway does not disappear before more funding is secured.
Brigham Hyde, CEO of Atropos Health, discussed with MobiHealthNews the crucial internal and external factors companies must...
California-based real-world data platform Atropos Health has secured $33 million in Series B funding.
Valtruis led the investment round, which included new investors McKesson Ventures, Merck GHI Fund and Cencora Ventures.
Existing investors Emerson Collective, Breyer Capital and Presidio Ventures also participated in the round.
Mike Spadafore, managing director of Valtruis, will join the...
California-based real-world data platform Atropos Health announced that healthcare data analytics company Arcadia has joined its health portfolio, giving Arcadia's provider customers and life sciences users access to Atropos' offerings.
Atropos Health offers AI innovations, evidence generation, analytics augmentation and data evaluation to help physicians access real-world evidence to guide...
California-based real-world data platform Atropos Health announced it completed a strategic financing round with participation from Sumitomo Corporation Venture Group's Presidio Ventures, Samsung Next, Audere Capital, Gaingels and other investors.
WHAT IT DOES
Atropos Health offers AI innovations, evidence generation, analytics augmentation and data evaluation to help physicians access real-...
Real-world data platform Atropos Health announced it appointed a life science advisory board and moved into the life sciences sector, offering AI innovations, data evaluation, evidence generation and analytics augmentation.
Atropos' app helps physicians access real-world evidence to guide clinical decisions and research.
The California-based company also offers its Green Button for clinical...
AI-backed remote monitoring and digital therapeutics company Biofourmis added another $20 million to its Series D round, bringing its raise to $320 million.
The extension funding comes from Intel Capital, the strategic investment division of chipmaker Intel. The company first announced its Series D in April, which boosted Biofourmis to unicorn status with a valuation of $1.3 billion.
Biofourmis...
